MedTrace Logo

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

NCT03419572 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 689

Last updated 2022-08-15

No results posted yet for this study

Summary

The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.

Conditions

Interventions

OTHER

Data collection

Only available evaluations as decided by the investigator based on local clinical practice will be collected.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-24
Primary Completion
2022-05-19
Completion
2022-05-19

Countries

  • Austria
  • Belgium
  • Czechia
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03419572 on ClinicalTrials.gov